MSB 3.19% 97.0¢ mesoblast limited

Cell Therapy News/Articles, page-34

  1. 3,829 Posts.
    lightbulb Created with Sketch. 1306
    That seems to be for Hepatitis C, not AGVHD so why the comparison. What are the other cures for AGVHD to compare with? For the FDA proof we have to wait for the publication of the phase III results.

    The pricing of any cell therapies will only be what the market will bear by comparison to the other options, a life time of medication or other outcomes.
    Last edited by Treed: 19/10/17
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.